Robert W. Baird set a price target of $95 for NASDAQ:MIRM, implying a potential upside of approximately 6.15% from recent levels. The stock reached an intraday high of $90.07, its highest point in the past year, and has demonstrated a year-to-date gain of roughly 3.4%, reflecting growing investor confidence. Trading volume over the past session was 1,229,452 shares, underscoring active interest in Mirum’s shares and signaling that market participants are closely monitoring the company’s upcoming catalysts.

Mirum reported preliminary, unaudited full-year 2025 net product sales of approximately $520 million, driven by an estimated $359 million in LIVMARLI revenues, including $243 million in U.S. sales—a 69% increase year-over-year—and combined CHOLBAM® and CTEXLI® sales of $161 million, up 31% from 2024. Fourth-quarter 2025 net product sales totaled an estimated $149 million, comprising $106 million from LIVMARLI and $43 million from CHOLBAM and CTEXLI. The company achieved positive cash flow from operations for the year and closed December 31, 2025 with approximately $392 million in cash, cash equivalents and investments, compared with $292.8 million at the end of 2024.

For full-year 2026, Mirum expects global net product sales in the range of $630 million to $650 million. Key clinical and corporate milestones include topline data from the volixibat VISTAS study in primary sclerosing cholangitis in Q2 2026; completion of enrollment for the LIVMARLI EXPAND Phase 3 trial in cholestatic pruritus in H1 2026 with topline results in Q4; and enrollment completion for the volixibat VANTAGE study in primary biliary cholangitis in H2 2026. The proposed acquisition of Bluejay Therapeutics and its brelovitug program for hepatitis delta virus is expected to close in mid-to-late January 2026, adding potential Phase 3 data readouts from the AZURE-1 study in HDV in both interim form in Q2 and full topline results in H2 2026.